三门峡地区β-内酰胺类抗菌药物致不良反应383例报告分析  

Adverse Drug Reactions Induced by Beta-lactam Antibiotics:Analysis of 383 Cases in Sanmenxia Area

作　　者：于丽[1] 李艳瑛[1] 李晋宝[1] 赵智峰[1] 

机构地区：[1]河南黄河三门峡医院,三门峡市472000

出　　处：《中国药房》2009年第14期1102-1104,共3页China Pharmacy

摘　　要：目的:了解三门峡地区β-内酰胺类抗菌药物致药品不良反应(ADR)的发生情况。方法:对2004年1月～2008年3月三门峡地区上报的383例β-内酰胺类抗菌药物致ADR报告,按性别、年龄、给药途径、药品类别、ADR涉及器官或系统及临床表现等进行统计、分析。结果:ADR涉及的β-内酰胺类抗菌药物共26种,ADR发生频次以头孢曲松钠居首位,其次为头孢唑啉钠;用药途径以静脉给药为主,占87.21%;主要的ADR类型为皮肤及其附件损害,占52.25%;3例严重ADR。结论:应规范β-内酰胺类抗菌药物的临床应用,以减少ADR的发生率。OBJECTIVE： To study the adverse drug reactions induced by beta - lactam antibiotics in Sanmenxia area. METHODS： A total of 383 ADR cases induced by beta - lactam antibiotics reported in Sanmenxia area from Jan. 2004 to Mar. 2008 were analyzed statistically in respect of patients＇ age and sex, route of administration, drug variety, organs or systems involved and the clinical manifestations etc. RESULTS： 26 kinds of beta- lactam antibiotics were involved in the ADR cases, leading the list was ceftriaxone followed by cefazolin sodium. Of all the drugs used in combination, Chinese materia medica preparations took the lead. 87.21% of the ADR cases were induced via intravenous route; 52.25% of the ADR manifested as lesions of skin and its appendants, and there were 3 serious ADR cases. CONCLUSION： The clinical application of Betalactam antibiotics should be standardized so as to reduce the ADR incidence.

关 键 词：β-内酰胺类抗茵药物 药品不良反应 联合用药 

分 类 号：R978.11[医药卫生—药品] R969.3[医药卫生—药学]